Papyrus Therapeutics

Scientific Advisory Board

Michael J Birrer

Expertise: Genomics of Gynecological Cancers

  • Vice-Chancellor of the University of Arkansas for Medical Sciences (UAMS) and Director of the Winthrop P. Rockefeller Cancer Institute
  • Former Professor of Medicine at Harvard Medical School and Director of Gynecologic Medical Oncology at Massachusetts General Hospital and the Gynecologic Oncology Research Program at the Dana Farber/Harvard Cancer Center
  • Former Chair of the Gynecologic Oncology Working Group, Division of Clinical Sciences, Deputy Branch Chief of Cell and Cancer Biology Branch, NCI

Raoul Chalres Coombes

Expertise: Cancer Drug Development, Translational Oncology, Cancel Clinical Trials

  • Professor of Medical Oncology, Imperial College, London and Co-director of the Imperial Breast Cancer Research Program
  • Expertise in estrogen receptor function in breast cancer and the specific role of CDK7 in endocrine resistant breast cancer
  • Chairman of the International Collaborative Cancer Group
  • 5 issued patents relating to breast cancer and novel therapies

Carl-Henrik Heldin

Expertise: Signal Transduction, Ligand and Receptor Tyrosine Kinase Biology

  • Professor in Molecular Cell Biology at Uppsala University and ex-Branch Director at the Ludwig Institute for Cancer Research
  • Chairman of the Boards of the Nobel Foundation
  • Chair of the Boards of the Science for Life Laboratory, and EMBL-node Molecular Infection Biology Sweden
  • Ex-Vice president of the European Research Council and Chair of the European Molecular Biology Organization until 2020

Jean Paul Thiery

Expertise: Cell Biology, Epithelial-Mesenchymal Transition, Stem Cell Science

  • Professor and Senior Scientist, National Laboratory Guangzhou, China
  • Former Deputy Director A*STAR IMCB Singapore
  • Head of translational research at Institut Curie Comprehensive Cancer Center, and head of CNRS laboratory at Ecole Normale Superieure, Paris
  • Co-Founder and Chairman of Biocheetah Pte. Ltd, a diagnostics company focused on urological cancers